VanEck Associates’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.3M Buy
262,281
+2,234
+0.9% +$109K 0.01% 525
2026
Q1
$11.2M Buy
260,047
+8,607
+3% +$370K 0.01% 567
2025
Q4
$11M Buy
251,440
+14,301
+6% +$592K 0.01% 534
2025
Q3
$9.79M Buy
237,139
+2,248
+1% +$90.4K 0.01% 554
2025
Q2
$10.4M Sell
234,891
-32,779
-12% -$1.31M 0.01% 476
2025
Q1
$9.88M Buy
267,670
+15,346
+6% +$547K 0.01% 483
2024
Q4
$8.4M Buy
252,324
+78,740
+45% +$2.55M 0.01% 511
2024
Q3
$4.92M Buy
173,584
+69,134
+66% +$1.72M 0.01% 649
2024
Q2
$2.35M Buy
+104,450
New +$2.32M ﹤0.01% 835
2022
Q3
Sell
-52,419
Closed -$1.09M 1398
2022
Q2
$1.09M Sell
52,419
-5,829
-10% -$120K ﹤0.01% 779
2022
Q1
$1.32M Buy
+58,248
New +$1.14M ﹤0.01% 785

Other funds holding EXEL

VanEck Associates's EXEL Position: Q2 2026 in Review

VanEck Associates increased its Exelixis (EXEL) stake by 0.86% in Q2 2026, buying an estimated $109K and bringing the position to 262,281 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #525.

VanEck Associates first reported a position in EXEL in Q1 2022 and has held it in 11 quarters since. 758 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • VanEck Associates held 262,281 shares of Exelixis worth $14.3M as of Q2 2026.
  • VanEck Associates bought 2,234 Exelixis shares in Q2 2026, an estimated $109K.
  • Exelixis made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #525 holding.
  • VanEck Associates first reported a position in Exelixis in Q1 2022 and has held it in 11 quarters since.
  • 758 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.